Electrochemical assays to detect more than 20 different substances in dermal interstitial fluid, including opioids, their metabolites, and affiliated medications. With sensing capabilities validated, FDA approval is in process for a micro-needle device.
Active Companies
https://www.carihealth.com
CARI Health received $4 Million in funding from the National Institute of Drug Abuse to develop its sensor device to combat the opioid crisis.
Forbes featured CARI's biosensor chip technology and its application in long-term alcohol or opioid monitoring.
CARI Health won the top cash prize of $300K at the 2022 San Diego Angel Conference.
CARI Health was named a 2022 Cool Company.
CARI Health was named a top 50 MedTech Innovator Accelerator team in 2022